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Premenstrual syndrome (PMS) is a hormone dependent pathophysiologic 
state with known somatic and affective symptoms. Vitamin D3 as a 
secosteroid hormone has different effects on several disorders. In this review, 
we declared some potential benefits of vitamin D3 regarding the alleviation 
of PMS symptoms; also, we have reported the results of the literature review 
about vitamin D and PMS. 
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Introduction 
Premenstrual syndrome (PMS) 
PMS is a hormone dependent pathophysiologic 
state. Physical and behavioral symptoms are appeared 
after ovulation and they seem to be progesterone 
dependent (1, 2). Although the pathophysiology of all 
PMS symptoms are not clarified up to now, bilateral 
interaction between sex hormones and 
neurotransmitters could explain some of these 
symptoms.  
Vitamin D3  
VD3 is a secosteroid hormone with well-
known musculoskeletal and extra-skeletal effects in 
several tissues (3). Although there are a number of 
studies that indicate the relation between low levels of 
vitamin D and pain syndromes (4, 5), the causative 
association was not shown till now.  
This review is arranged in three parts. First it is 
focused on proposed cellular and molecular 
mechanisms of pain as one of the major 
manifestations of PMS, then the published literature 
in pubmed about the vitamin D and PMS were 
discussed and at the last section the hypothesis 
regarding the possible effects of vitamin D3 on pain 
reducing in PMS cases were accounted. 
Potential cellular and molecular mechanisms of 
PMS symptoms  
Among the most common complications of 
PMS are abdominal cramps and headache.  
The underlying mechanism of pain in PMS is 
not fully understood. One of the pathophysiologic 
interpretations of the pain in PMS is related to 
progesterone metabolites (6). Although the symptoms 
of PMS are initiated in luteal phase of menstruation 
cycle, which is concurrent with progesterone release 
by corpus luteum (7), It seems that progesterone 
levels are not different between PMS and non PMS 
women (8) and it could not per se be the etiology of 
PMS syndromes (9).  
The pattern of progesterone changes during 
menstrual cycles has important role in symptom 
creation of PMS cases. A recent study also showed 
that  
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Table 1: Articles investigated the effects of vitamin D supplementation in PMS cases. 
Article’s title Year  Study design Dose and duration of vitamin D 
prescription  
Outcomes  
Vitamin D supplementation for 
premenstrual syndrome-related 
mood disorders in adolescents 
with severe hypovitaminosis D 
(35) 
2016 Randomized clinical trial 
(15-21 years old women 
with severe PMS 
affective symptoms and 
hypo-vitaminosis D)  
200,000 IU vitamin D at first, followed 
by 25,000 IU (every 2 weeks) for a 4-
month period  
The severity of affective 
symptoms were 
decreased with vitamin 
D intake in treatment 
group 
No effect on nausea and 
constipation was seen  
Calcium versus oral contraceptive 
pills containing drospirenone for 
the treatment of mild to moderate 
premenstrual syndrome: a double 
blind randomized placebo 
controlled trial (36) 
2016 Double-blind 
randomized placebo 
controlled trial, mild to 
moderate premenstrual 
syndrome 
Three groups, 1: combined OCP, 2: 
vitamin D/Ca (400 IU/(400 mg), 3: 
placebo 
Prescription of drugs started from 3rd 
day of menstruation up to 2 days for 3 
months 
The proportion of 
women with improved 
symptoms increased in 
groups 1 and 2 
compared to 3 
Severity of PMS 
problems decreased in 
groups 1 and 2 
compared to 3 
Evaluating the effects of vitamin 
D and vitamin E supplement on 
premenstrual syndrome: A 
randomized, double-blind, 
controlled trial (37) 
2016 Double-blind 
randomized controlled 
trial (15-45 years old 
women with known 
PMS) 
Three groups, 1: vitamin D (200mg/ 
day), 2: vitamin E (100mg/day), 3: 
placebo (one/day) 
supplementation was provided from the 
first to the last day of menstruation cycle 
for 2 months  
Mean PMS scores of all 
three groups were 
decreased after 
intervention 
There was not any 
significant difference 
between three groups  
Effect of treatment with 
dydrogesterone or calcium plus 
vitamin D on the severity of 




controlled trial  
(Severe PMS women) 
Three groups, 1: two tablets each 
contained 5 mg dydrogesterone, 2: two 
tablets each contained 500mg Ca/200 
mg vitamin D, 3: two placebo tablets 
from day 15 to 24 of two menstrual 
cycles 
 
Symptom severity was 
decreased in all 3 
groups 
Decrease in severity is 
more related to 
emotional symptoms 
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Calcium-regulating hormones 
across the menstrual cycle: 
evidence of a secondary 
hyperparathyroidism in women 
with PMS (39) 
1995  One patient with PMS was treated with 
Ca/vitamin  
D3 for three months 
Symptoms of PMS were 
ameliorated in treated 
patient 
Vitamin D and calcium in 
menstrual migraine (40) 
 
1994  Two patients with PMS and 
menstrually-related migraines were 
treated with Ca/vitamin D for 2 months 
Menstrual migraine 
attacks and PMS 
symptoms were 
decreased 
women without PMS symptoms experience more 
gradual declining pattern of progesterone during 
luteal phase compared to PMS cases. Women with 
PMS experience a sharp drop in progesterone level in 
late luteal phase after an almost stable progesterone 
levels during most of the secretory phase (10).   
Besides the pattern of progesterone 
fluctuations, progesterone metabolites have important 
role in pain establishment. Progesterone is converted 
to neurosteroids like pregnanolone and 
allopregnanolone during its metabolism and these 
metabolites play critical roles in PMS manifestations 
(6). Negative mood symptoms of PMS patients are 
recorded in allopregnanolone concentrations which 
are similar to their natural serum concentrations in 
luteal phases. In higher or lower concentrations, the 
mood symptoms are alleviated (11). This pattern 
could be symbolized as a reverted U shape pattern.  
As allopregnanolone and pregnanolone are 
positive allosteric modulators in GABA system (12-
14) and GABA-receptor is the prominent inhibitory 
system in CNS (15), we could expect sedative effects 
for these compounds. Unlike our expectations, it was 
shown that these neurosteroids could modify the 
sensitivity of GABA(A) receptor to the ligand and 
induce pain and irritability instead of expected 
calming and anxiolytic effects in PMS patients (6, 
16). In line with this phenomenon, it was shown that 
pain sensitivity is increased in luteal phase of 
menstruation compared to follicular phase (17).  
The pain in PMS also could be related to 
decreased levels of endorphins in these cases (18, 19). 
There is evidence of upraised cold pain and pressure 
pain sensitivity in young females with menstrual 
pains (20). Iacovides et al stated greater pain 
sensitivity in women with dysmenorrhea along their 
menstrual cycles (21). Also, increased expression of 
pro-inflammatory cytokines and decreased levels of 
transforming growth factor family were reported in 
women with primary dysmenorrhea (22).  
The other cause of pain in PMS is related to 
prostaglandin production. The urinary excretion of 
prostaglandin E2 and F2α are decreased in PMS 
women compared to controls (23). Thus increased 
levels of these prostaglandins may contribute for pain 
related findings in PMS women.   
Vitamin D3 effects on PMS 
Vitamin D3 is a secosteroid hormone with 
multi-organ targets. There are two main sources for 
vitamin D3 in human; photosynthesis in skin and food 
intake. The main circulatory form of vitamin D3 is 25 
hydroxy vitamin D3 which resulted from 25 
hydroxylation of vitamin D3 in liver (3). 
Vitamin D3 has known hormonal, metabolic 
and immune-modulatory functions in different organ 
systems including musculoskeletal, cardiovascular 
(24, 25), immune system (26, 27), reproductive 
system (28-31) and so on. 
Many studies investigated the vitamin D3 in 
pain syndromes, including PMS (32-34). Next 
paragraphs discuss vitamin D and PMS literatures. 
Search strategy and results 
We searched pubmed with these key words 
“premenstrual syndrome” and “vitamin D”. This 
search resulted in 26 articles. We found 14 original 
articles that contained in somehow these key words in 
their abstracts. We categorized these articles based on 
study design. In six studies (35-40) the effects of  
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Table 2: Articles investigated the association between vitamin D levels and PMS. 
Article’s title Year  Study design Results  
The relationship between serum 
vitamin D level and premenstrual 
syndrome in Iranian women (41) 
2016 Case-control study two 
Iranian groups: 1. PMS group 
2. Control group 
There was not any significant 
difference between 25(OH)D 
levels between two groups. 
The association between the risk of 
premenstrual syndrome and vitamin D, 
calcium, and magnesium status among 
university students: a case control 
study (42) 
2015 Case-control study, Two 
groups (PMS and control) 
consisted 20-25 years old 
women 
Vitamin D levels are not 
statistically different between 
groups (the risk of PMS in 
association with vitamin D 
was not measured)    
Plasma 25-hydroxyvitamin D and risk 
of premenstrual syndrome in a 
prospective cohort study (43) 
2014 Prospective cohort study, 
Two groups were enrolled: 1. 
PMS cases which are 
categorized based on time of 
blood sampling (before or 
after PMS diagnosis), 
Group 2. 
 non PMS controls 
The overall risk of PMS was 
not associated with 25(OH) 
D levels. 
In cases that develop PMS 
after blood collection 
25(OH)D levels are 
associated with lower risk of 
some of PMS symptoms 
Premenstrual symptoms in 
dysmenorrheic college students: 
prevalence and relation to vitamin D 
and parathyroid hormone levels (44) 
2012 Cross sectional study with 
recruitment of 18-24 years 
old women with primary 
dysmenorrhea,    
There is not association 
between 25(OH)D and 
premenstrual symptoms in 
18-24 years old women with 
primary dysmenorrhea 
Dietary vitamin D intake, 25-
hydroxyvitamin D3 levels and 
premenstrual syndrome in a college-
aged population (45) 
2010 Cross sectional case control 
study of women between 18-
30 years old 
No statistical significant 
difference in 25(OH)vitamin 
D levels was seen in PMS 
cases with minimal, moderate 
and severe symptoms 
The levels of 25(OH)D3 
were not associated to the 
risk of PMS 
Cyclical changes in calcium 
metabolism across the menstrual cycle 
in women with premenstrual dysphoric 
disorder (46) 
2007 cross-sectional prospective 
study, two groups were 
included in the study; 
premenstrual dysphoric 
The levels of 25(OH)D3 
were not statistically different 
between two groups 
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disorder and control groups 
Calcium-regulating hormones across 
the menstrual cycle: evidence of a 
secondary hyperparathyroidism in 
women with PMS (39)  
1995 Case control study, two 
groups of PMS and control 
were investigated 
The levels of 25OHD was 
significantly lower in PMS 
group during all phases of 
menstruation cycle compared 
to control group    
 
vitamin D3 supplementation on PMS or its symptoms 
were studies (Table 1). We found seven articles (39, 
41-46) in which the authors study the association 
between vitamin D levels and PMS (Table 2), from 
these articles, three (43-45) are related to the risk of 
PMS. One of these articles is shared between two 
categories (39). There was an article which was 
designed based on the vitamin D and calcium intake 
according to semi-quantitative food frequency 
questionnaire in PMS and control groups (47). As this 
study was not based on supplementation of vitamin D, 
the results were not consisted in table 1.  
All of studies related to vitamin D 
supplementation (35-40) indicated that providing 
vitamin D3 could ameliorate the severity of the most 
somatic and affective PMS symptoms. However the 
optimum dose of vitamin D3 supplementation and 
also the best duration of treatment for improving the 
symptoms need to be declared. Also more studies for 
investigating the effects of vitamin D especially on 
pain severity seem to be necessary.   
Several studies investigated the relationship 
between 25(OH)D as the main circulatory form of 
vitamin D and PMS (39, 41-46). The majority of 
these articles could not show any significant 
difference between the PMS and control groups (41-
46), except for Thys-jacob et al study (39). Also it is 
important to emphasize that Obeidat et al indicated no 
association between vitamin D levels and 
premenstrual symptoms in dysmenorrheic patients 
instead of PMS ones (44). 
Conclusion 
Vitamin D could be effective on many PMS 
symptoms. The exact mechanisms of these actions are 
not completely discovered. Shipton et al explained 
proposed effects of vitamin D on chronic pain 
syndromes (48). Some of these effects could be 
involved in PMS as well. Vitamin D could inhibit 
cyclooxygenase 2 and nitic oxide synthase. These 
effects could result in decreasing prostaglandin and 
nitric oxide levels, with final pain modulatory effects. 
Vitamin D as an anti-inflammatory agent could affect 
PMS through upraising anti-inflammatory cytokines 
such as transforming growth factor β and decreasing 
inflammatory ones such as tumor necrosis factor α in 
CNS. Vitamin D has modulatory effects on 
neuroexcitation and in this way it could influence pain 
related symptoms. Vitamin D could upregulate 
several neurotrophins and also alter neurotransmitter 
receptors and ion channels in CNS (48, 49). All of 
above mentioned mechanisms could be involved in 
pain amelioration in PMS.       
This study has 3 main results: 
1- The hypothetical mechanisms relating the 
effect of vitamin D on PMS pain is relatively well 
described and involves a wide range of anti-
inflammatory interactions and neurological 
mechanisms of chronic pain affected by vitamin D 
in PMS patients 
2- The clinical outcome of PMS patients is not 
vividly proved to be affected by vitamin D 
administration in large RCT’s; though there are 
some pro-vitamin D studies, showing clinical 
effect of vitamin D in PMS 
3- Large multicenter clinical studies with valid 
laboratory bench marking is still needed to make 
evidence-based decision in order to give 
supplemental vitamin D in PMS patients to relieve 
pain; till then, the final word regarding clinical 
effects of vitamin D on PMS pain is to be said. 
Acknowledgment 
This research has been done by the grant of 
Research Deputy, Tehran University of Medical 
Sciences (Grant number 91-02-31-17711); the authors 
would like to acknowledge the kind assistance and 
The molecular mechanisms of Vitamin D effects on alleviating                                                                   Rajaei et al.  
Vol 2, No 1, Winter 2017 
35 
help of Research Deputy, Tehran University of 
Medical Sciences, Tehran, Iran. None of the authors 
has any conflict of interest throughout the manuscript. 
Conflicts of Interest 
The authors declare that there are no conflicts 
of interest. 
References 
1. Biggs WS, Demuth RH. Premenstrual syndrome and 
premenstrual dysphoric disorder. Am Fam Physician. 
2011;84(8):918-24.  
2. Braverman PK. Premenstrual Syndrome and Premenstrual 
Dysphoric Disorder. Journal of Pediatric and Adolescent 
Gynecology. 2007 2//;20(1):3-12. 
3. Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. 
The Journal of steroid biochemistry and molecular biology. 2016.  
4. Straube S, Derry S, Moore RA, McQuay HJ. Vitamin D for the 
treatment of chronic painful conditions in adults. The Cochrane 
database of systematic reviews. 2010; 20(1):Cd007771.  
5. Straube S, Andrew Moore R, Derry S, McQuay HJ. Vitamin D 
and chronic pain. Pain. 2009;141(1-2):10-3.  
6. Backstrom T, Bixo M, Stromberg J. GABAA Receptor-
Modulating Steroids in Relation to Women's Behavioral Health. 
Current psychiatry reports. 2015;17(11):92.  
7. Backstrom T, Andreen L, Birzniece V, Bjorn I, Johansson IM, 
Nordenstam-Haghjo M, et al. The role of hormones and hormonal 
treatments in premenstrual syndrome. CNS drugs. 2003;17(5):325-
42.  
8. Backstrom T, Sanders D, Leask R, Davidson D, Warner P, 
Bancroft J. Mood, sexuality, hormones, and the menstrual cycle. II. 
Hormone levels and their relationship to the premenstrual syndrome. 
Psychosomatic medicine. 1983 Dec;45(6):503-7. PubMed PMID: 
6686333. Epub 1983/12/01. Eng. 
9. Rapkin AJ, Akopians AL. Pathophysiology of premenstrual 
syndrome and premenstrual dysphoric disorder. Menopause 
international. 2012;18(2):52-9.  
10. Lovick TA, Guapo VG, Anselmo-Franci JA, Loureiro CM, 
Faleiros MC, Del Ben CM, et al. A specific profile of luteal phase 
progesterone is associated with the development of premenstrual 
symptoms. Psychoneuroendocrinology. 2016;75:83-90.  
11. Andreen L, Sundstrom-Poromaa I, Bixo M, Nyberg S, 
Backstrom T. Allopregnanolone concentration and mood--a bimodal 
association in postmenopausal women treated with oral 
progesterone. Psychopharmacology. 2006;187(2):209-21.  
12. Paul SM, Purdy RH. Neuroactive steroids. FASEB journal : 
official publication of the Federation of American Societies for 
Experimental Biology. 1992;6(6):2311-22.  
13. Rupprecht R. Neuroactive steroids: mechanisms of action and 
neuropsychopharmacological properties. Psychoneuroendocrin-
ology. 2003;28(2):139-68.  
14. Vanover KE, Suruki M, Robledo S, Huber M, Wieland S, Lan 
NC, et al. Positive allosteric modulators of the GABA(A) receptor: 
differential interaction of benzodiazepines and neuroactive steroids 
with ethanol. Psychopharmacology. 1999;141(1):77-82.  
15. Kuffler SW, Edwards C. Mechanism of gamma aminobutyric 
acid (GABA) action and its relation to synaptic inhibition. Journal of 
neurophysiology. 1958;21(6):589-610.  
16. Bäckström T, Bixo M, Johansson M, Nyberg S, Ossewaarde L, 
Ragagnin G, et al. Allopregnanolone and mood disorders. Progress 
in Neurobiology. 2014;113:88-94. 
17. Fillingim RB, Ness TJ. Sex-related hormonal influences on pain 
and analgesic responses. Neuroscience & Biobehavioral Reviews. 
2000;24(4):485-501. 
18. Halbreich U, Endicott J. Possible involvement of endorphin 
withdrawal or imbalance in specific premenstrual syndromes and 
postpartum depression. Medical Hypotheses. 1981;7(8):1045-58. 
19. Cubeddu A, Bucci F, Giannini A, Russo M, Daino D, Russo N, 
et al. Brain-derived neurotrophic factor plasma variation during the 
different phases of the menstrual cycle in women with premenstrual 
syndrome. Psychoneuroendocrinology. 2011;36(4):523-30. 
20. Slater H, Paananen M, Smith AJ, O'Sullivan P, Briggs AM, 
Hickey M, et al. Heightened cold pain and pressure pain sensitivity 
in young female adults with moderate-to-severe menstrual pain. 
Pain. 2015;156(12):2468-78.  
21. Iacovides S, Avidon I, Baker FC. What we know about primary 
dysmenorrhea today: a critical review. Human reproduction update. 
2015;21(6):762-78.  
22. Ma H, Hong M, Duan J, Liu P, Fan X, Shang E, et al. Altered 
Cytokine Gene Expression in Peripheral Blood Monocytes across 
the Menstrual Cycle in Primary Dysmenorrhea: A Case-Control 
Study. PLoS ONE. 2013;8(2):e55200.  
23. Piccoli A, Modena F, Calo L, Cantaro S, Avogadro A, Nardo G, 
et al. Reduction in urinary prostaglandin excretion in the 
premenstrual syndrome. The Journal of reproductive medicine. 
1993;38(12):941-4.  
24. Perez-Hernandez N, Aptilon-Duque G, Nostroza-Hernandez 
MC, Vargas-Alarcon G, Rodriguez-Perez JM, Blachman-Braun R. 
Vitamin D and its effects on cardiovascular diseases: a 
comprehensive review. The Korean journal of internal medicine. 
2016;31(6):1018-29.  
25. Michos ED, Selvin E, Misialek JR, McEvoy JW, Ndumele CE, 
Folsom AR, et al. 25-Hydroxyvitamin D Levels and Markers of 
Subclinical Myocardial Damage and Wall Stress: The 
Atherosclerosis Risk in Communities Study. Journal of the 
American Heart Association. 2016;5(11).  
26. Bikle DD. Extraskeletal actions of vitamin D. Annals of the 
New York Academy of Sciences. 2016;1376(1):29-52.  
27. White JH. Vitamin D metabolism and signaling in the immune 
system. Reviews in endocrine & metabolic disorders. 2012;13(1):21-
9.  
28. Franasiak JM. Vitamin D in human reproduction-an evolving 
landscape. Fertility and sterility. 2016.  
29. Pacis MM, Fortin CN, Zarek SM, Mumford SL, Segars JH. 
Vitamin D and assisted reproduction: should vitamin D be routinely 
screened and repleted prior to ART? A systematic review. Journal of 
assisted reproduction and genetics. 2015;32(3):323-35.  
30. Rajaei S, Mirahmadian M, Jeddi-Tehrani M, Tavakoli M, 
Zonoobi M, Dabbagh A, et al. Effect of 1,25(OH)2 vitamin D3 on 
cytokine production by endometrial cells of women with repeated 
implantation failure. Gynecological endocrinology: the official 
Rajaei et al.                                                                        The molecular mechanisms of Vitamin D effects on alleviating 
 Journal of Cellular & Molecular Anesthesia (JCMA) 
36 
journal of the International Society of Gynecological Endocrinology. 
2012;28(11):906-11.  
31. Tavakoli M, Jeddi-Tehrani M, Salek-Moghaddam A, Rajaei S, 
Mohammadzadeh A, Sheikhhasani S, et al. Effects of 1,25(OH)2 
vitamin D3 on cytokine production by endometrial cells of women 
with recurrent spontaneous abortion. Fertility and sterility. 
2011;96(3):751-7.  
32. von Kanel R, Muller-Hartmannsgruber V, Kokinogenis G, 
Egloff N. Vitamin D and central hypersensitivity in patients with 
chronic pain. Pain medicine (Malden, Mass). 2014;15(9):1609-18.  
33. Jesus CA, Feder D, Peres MF. The role of vitamin D in 
pathophysiology and treatment of fibromyalgia. Current pain and 
headache reports. 2013;17(8):355.  
34. Huang W, Shah S, Long Q, Crankshaw AK, Tangpricha V. 
Improvement of pain, sleep, and quality of life in chronic pain 
patients with vitamin D supplementation. The Clinical journal of 
pain. 2013;29(4):341-7.  
35. Tartagni M, Cicinelli MV, Tartagni MV, Alrasheed H, Matteo 
M, Baldini D, et al. Vitamin D Supplementation for Premenstrual 
Syndrome-Related Mood Disorders in Adolescents with Severe 
Hypovitaminosis D. J Pediatr Adolesc Gynecol. 2016 
Aug;29(4):357-61. PubMed PMID: 26724745. Epub 2016/01/03. 
Eng. 
36. Shehata NA. Calcium versus oral contraceptive pills containing 
drospirenone for the treatment of mild to moderate premenstrual 
syndrome: a double blind randomized placebo controlled trial. 
European journal of obstetrics, gynecology, and reproductive 
biology. 2016;198:100-4.  
37. Dadkhah H, Ebrahimi E, Fathizadeh N. Evaluating the effects of 
vitamin D and vitamin E supplement on premenstrual syndrome: A 
randomized, double-blind, controlled trial. Iranian journal of nursing 
and midwifery research. 2016;21(2):159-64.  
38. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect 
of treatment with dydrogesterone or calcium plus vitamin D on the 
severity of premenstrual syndrome. Int J Gynaecol Obstet. 
2009;105(2):158-61.  
39. Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across 
the menstrual cycle: evidence of a secondary hyperparathyroidism in 
women with PMS. J Clin Endocrinol Metab. 1995;80(7):2227-32.  
40. Thys-Jacobs S. Vitamin D and calcium in menstrual migraine. 
Headache. 1994;34(9):544-6.  
41. Rajaei S, Akbari Sene A, Norouzi S, Berangi Y, Arabian S, Lak 
P, et al. The relationship between serum vitamin D level and 
premenstrual syndrome in Iranian women. Int J Reprod Biomed. 
2016;14(10):665-8. 
42. Saeedian Kia A, Amani R, Cheraghian B. The Association 
between the Risk of Premenstrual Syndrome and Vitamin D, 
Calcium, and Magnesium Status among University Students: A Case 
Control Study. Health Promot Perspect. 2015;5(3):225-30.  
43. Bertone-Johnson ER, Hankinson SE, Forger NG, Powers SI, 
Willett WC, Johnson SR, et al. Plasma 25-hydroxyvitamin D and 
risk of premenstrual syndrome in a prospective cohort study. BMC 
Womens Health. 2014;14:56.  
44. Obeidat BA, Alchalabi HA, Abdul-Razzak KK, Al-Farras MI. 
Premenstrual symptoms in dysmenorrheic college students: 
prevalence and relation to vitamin D and parathyroid hormone 
levels. Int J Environ Res Public Health. 2012;9(11):4210-22.  
45. Bertone-Johnson ER, Chocano-Bedoya PO, Zagarins SE, Micka 
AE, Ronnenberg AG. Dietary vitamin D intake, 25-hydroxyvitamin 
D3 levels and premenstrual syndrome in a college-aged population. 
The Journal of steroid biochemistry and molecular biology. 
2010;121(1-2):434-7.  
46. Thys-Jacobs S, McMahon D, Bilezikian JP. Cyclical changes in 
calcium metabolism across the menstrual cycle in women with 
premenstrual dysphoric disorder. J Clin Endocrinol Metab. 
2007;92(8):2952-9.  
47. Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, 
Willett WC, Manson JE. Calcium and vitamin D intake and risk of 
incident premenstrual syndrome. Archives of internal medicine. 
2005;165(11):1246-52.  
48. Shipton EA, Shipton EE. Vitamin D and Pain: Vitamin D and 
Its Role in the Aetiology and Maintenance of Chronic Pain States 
and Associated Comorbidities. Pain Research and Treatment. 2015. 
49. Shipton EE, Shipton EA. Vitamin D Deficiency and Pain: 
Clinical Evidence of Low Levels of Vitamin D and Supplementation 
in Chronic Pain States. Pain and therapy. 2015;4(1):67-87.  
 
